FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011303023> ?p ?o ?g. }

• W2011303023 endingPage "231" @default.
• W2011303023 startingPage "218" @default.
• W2011303023 abstract "Background: It is unclear how best to measure sedative/analgesic drug exposure in the clinical care of critically ill patients. Large doses and prolonged use of sedatives and analgesics in the intensive care unit (ICU) may lead to oversedation and adverse effects, including delirium and long-term cognitive impairment. These issues are of particular concern in elderly patients (aged ≥65 years), who account for at least half of all ICU admissions and nearly two thirds of ICU days. Objective: This pilot study explored the relationships between clinical sedation scores, sedative/analgesic drug doses, and plasma drug concentrations in critically ill patients, the majority of whom were elderly. Methods: This was a prospective, observational study conducted in a 500-bed, tertiary care community hospital. Study patients included a cohort of mechanically ventilated, medical ICU patients who were admitted to the hospital between April and June 2004 who required use of fentanyl, lorazepam, or propofol. Sedative/analgesic medications were administered according to clinical guidelines. Patients' sedation levels were measured twice daily using the Richmond Agitation-Sedation Scale (RASS). Dosing of fentanyl, lorazepam, and propofol was recorded. Blood was sampled twice daily for up to 5 days to analyze plasma drug concentrations. To specifically evaluate the effects of acute, extended (rather than chronic) sedative and analgesic exposure, the study focused on an ICU population receiving these agents for at least 48 hours but <2 weeks. Results: Eighteen medical ICU patients (11 females, 7 males; mean [SD] age, 66.1 [18.1] years) on mechanical ventilation comprised the study cohort. Fifteen patients were aged >62 years, and 11 of those were aged ≥71 years. Plasma drug concentrations (median and interquartile range) were as follows: fentanyl—2.1 ng/mL, 0.9–3.4 ng/mL; lorazepam—266 ng/mL, 112-412 ng/mL; and propofol—845 ng/mL, 334-1342 ng/mL. Maximum concentrations were 3- to 12-fold higher than medians (fentanyl, 7.3 ng/mL; lorazepam, 3108 ng/mL; propofol, 10,000 ng/mL). Medication doses were only moderately correlated with RASS scores (Spearman ρ): fentanyl—ρ = −0.39, P = 0.002; lorazepam—ρ = −0.28, P = 0.001; and propofol—ρ = −0.46, P < 0.001. Plasma drug concentrations of fentanyl and lorazepam demonstrated moderate correlations with sedation scores (fentanyl—ρ = −0.46, P = 0.002; lorazepam: ρ = −0.49, P < 0.001), while propofol concentrations correlated poorly with sedation scores (ρ = −0.18, P = 0.07). Associations between interval drug doses and plasma concentrations were as follows: fentanyl, ρ = 0.84; lorazepam, ρ = 0.76; and propofol, ρ = 0.61 (all, P < 0.001). Instructive examples of discrepant dose versus plasma concentration profiles and drug interactions are provided, including 3 cases with patients aged ≥64 years. Conclusions: Elderly patients are commonly encountered in the ICU setting. Only moderate correlations existed between clinical sedation levels and dose or plasma concentration of sedative/analgesic medications in this study population. Further work is needed to understand appropriate and feasible measures of exposure to sedatives/analgesics relating to clinical outcomes. ( Am J Geriatr Pharmacother . 2007;5:218-231)." @default.
• W2011303023 created "2016-06-24" @default.
• W2011303023 creator A5009058069 @default.
• W2011303023 creator A5009929650 @default.
• W2011303023 creator A5010011309 @default.
• W2011303023 creator A5019482923 @default.
• W2011303023 creator A5022648071 @default.
• W2011303023 creator A5025056027 @default.
• W2011303023 creator A5027237893 @default.
• W2011303023 creator A5028596742 @default.
• W2011303023 creator A5033194385 @default.
• W2011303023 creator A5071303342 @default.
• W2011303023 creator A5074852854 @default.
• W2011303023 creator A5081691274 @default.
• W2011303023 date "2007-09-01" @default.
• W2011303023 modified "2023-09-27" @default.
• W2011303023 title "Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients" @default.
• W2011303023 cites W1925943257 @default.
• W2011303023 cites W1970301515 @default.
• W2011303023 cites W1972017211 @default.
• W2011303023 cites W1977854014 @default.
• W2011303023 cites W1980959248 @default.
• W2011303023 cites W1981698550 @default.
• W2011303023 cites W1981797192 @default.
• W2011303023 cites W1981844489 @default.
• W2011303023 cites W1984441096 @default.
• W2011303023 cites W1985624905 @default.
• W2011303023 cites W2014306174 @default.
• W2011303023 cites W2014329907 @default.
• W2011303023 cites W2016922039 @default.
• W2011303023 cites W2029216908 @default.
• W2011303023 cites W2037505626 @default.
• W2011303023 cites W2037614372 @default.
• W2011303023 cites W2039613248 @default.
• W2011303023 cites W2043822514 @default.
• W2011303023 cites W2053253235 @default.
• W2011303023 cites W2055028830 @default.
• W2011303023 cites W2059265071 @default.
• W2011303023 cites W2062518481 @default.
• W2011303023 cites W2064268214 @default.
• W2011303023 cites W2064590051 @default.
• W2011303023 cites W2066712893 @default.
• W2011303023 cites W2071853044 @default.
• W2011303023 cites W2072870313 @default.
• W2011303023 cites W2088205404 @default.
• W2011303023 cites W2099066338 @default.
• W2011303023 cites W2100709866 @default.
• W2011303023 cites W2104718526 @default.
• W2011303023 cites W2107251730 @default.
• W2011303023 cites W2121108496 @default.
• W2011303023 cites W2123098876 @default.
• W2011303023 cites W2124314037 @default.
• W2011303023 cites W2127103549 @default.
• W2011303023 cites W2134210134 @default.
• W2011303023 cites W2140066904 @default.
• W2011303023 cites W2157471359 @default.
• W2011303023 cites W2162055755 @default.
• W2011303023 cites W2162239413 @default.
• W2011303023 cites W2179437225 @default.
• W2011303023 cites W2322707526 @default.
• W2011303023 cites W2485082676 @default.
• W2011303023 cites W2979021191 @default.
• W2011303023 cites W875859 @default.
• W2011303023 cites W2107978811 @default.
• W2011303023 doi "https://doi.org/10.1016/j.amjopharm.2007.10.005" @default.
• W2011303023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17996661" @default.
• W2011303023 hasPublicationYear "2007" @default.
• W2011303023 type Work @default.
• W2011303023 sameAs 2011303023 @default.
• W2011303023 citedByCount "21" @default.
• W2011303023 countsByYear W20113030232012 @default.
• W2011303023 countsByYear W20113030232013 @default.
• W2011303023 countsByYear W20113030232014 @default.
• W2011303023 countsByYear W20113030232016 @default.
• W2011303023 countsByYear W20113030232017 @default.
• W2011303023 countsByYear W20113030232018 @default.
• W2011303023 countsByYear W20113030232019 @default.
• W2011303023 crossrefType "journal-article" @default.
• W2011303023 hasAuthorship W2011303023A5009058069 @default.
• W2011303023 hasAuthorship W2011303023A5009929650 @default.
• W2011303023 hasAuthorship W2011303023A5010011309 @default.
• W2011303023 hasAuthorship W2011303023A5019482923 @default.
• W2011303023 hasAuthorship W2011303023A5022648071 @default.
• W2011303023 hasAuthorship W2011303023A5025056027 @default.
• W2011303023 hasAuthorship W2011303023A5027237893 @default.
• W2011303023 hasAuthorship W2011303023A5028596742 @default.
• W2011303023 hasAuthorship W2011303023A5033194385 @default.
• W2011303023 hasAuthorship W2011303023A5071303342 @default.
• W2011303023 hasAuthorship W2011303023A5074852854 @default.
• W2011303023 hasAuthorship W2011303023A5081691274 @default.
• W2011303023 hasConcept C126322002 @default.
• W2011303023 hasConcept C177713679 @default.
• W2011303023 hasConcept C194828623 @default.
• W2011303023 hasConcept C2776277131 @default.
• W2011303023 hasConcept C2776376669 @default.
• W2011303023 hasConcept C2776814716 @default.
• W2011303023 hasConcept C2777080012 @default.
• W2011303023 hasConcept C2777288759 @default.

• next